21 analysts have shared their evaluations of Exelixis EXEL during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 7 | 7 | 0 | 0 |
| Last 30D | 2 | 1 | 2 | 0 | 0 |
| 1M Ago | 3 | 6 | 3 | 0 | 0 |
| 2M Ago | 2 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $38.71, a high estimate of $45.00, and a low estimate of $29.00. Surpassing the previous average price target of $35.67, the current average has increased by 8.52%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Exelixis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Lebowitz | Citigroup | Raises | Buy | $45.00 | $38.00 |
| Michael Schmidt | Guggenheim | Maintains | Buy | $42.00 | $42.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Equal-Weight | $29.00 | $29.00 |
| Stephen Willey | Stifel | Raises | Hold | $36.00 | $30.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $38.00 | $37.00 |
| Ashwani Verma | UBS | Raises | Neutral | $34.00 | $30.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $41.00 | $41.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $43.00 | $42.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Equal-Weight | $29.00 | $29.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $40.00 | $40.00 |
| Jefferson Harralson | Morgan Stanley | Raises | Overweight | $40.00 | $30.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $33.00 | $41.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $41.00 | $41.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $41.00 | $38.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $42.00 | $38.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $41.00 | $34.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $37.00 | $36.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $40.00 | $29.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $42.00 | $33.00 |
| Etzer Darout | BMO Capital | Raises | Market Perform | $40.00 | $36.00 |
| Jason Gerberry | B of A Securities | Raises | Neutral | $39.00 | $35.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exelixis's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Exelixis analyst ratings.
Unveiling the Story Behind Exelixis
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis: Financial Performance Dissected
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 14.33%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 4.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
